2.50
Hdl Handle:
http://hdl.handle.net/10541/72314
Title:
RADPLAT: an alternative to surgery?
Authors:
Alkureishi, Lee W T; De Bree, Remco; Ross, Gary L
Abstract:
Head and neck cancer frequently presents at a late stage, leading to a poor prognosis despite optimal treatment with surgery and/or radiotherapy. Chemotherapy for advanced disease has shown little benefit as a single-modality treatment, and the use of concurrent chemoradiation is limited by problems with severe toxicity at higher doses. RADPLAT is the acronym used to describe a new technique, combining intra-arterial delivery of cisplatin with systemic neutralization by i.v. sodium thiosulphate, and concurrent radiotherapy. This allows very high cisplatin dose intensities to be used while potentially minimizing adverse systemic effects. Initial results suggest that excellent locoregional control rates are achievable in patients with unresectable disease, with a favorable side-effect profile when compared with conventional chemoradiation protocols. In addition, RADPLAT may potentially be of benefit in selected patients with resectable disease, allowing for preservation of organ function and quality of life without compromising locoregional control or survival. While current phase II data are encouraging, phase III randomized controlled trials are required in order to directly compare RADPLAT with i.v. chemoradiation therapy, the current standard of care. This article reviews the evolution of the RADPLAT concept, from initial clinical trials to its current application in the treatment of patients with advanced head and neck cancer.
Affiliation:
Department of Plastic Surgery, Christie Hospital, Southmoor Road, Manchester, United Kingdom, and Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands.
Citation:
RADPLAT: an alternative to surgery? 2006, 11 (5):469-80 Oncologist
Journal:
The Oncologist
Issue Date:
May-2006
URI:
http://hdl.handle.net/10541/72314
DOI:
10.1634/theoncologist.11-5-469
PubMed ID:
16720847
Type:
Article
Language:
en
ISSN:
1083-7159
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAlkureishi, Lee W T-
dc.contributor.authorDe Bree, Remco-
dc.contributor.authorRoss, Gary L-
dc.date.accessioned2009-07-02T15:58:59Z-
dc.date.available2009-07-02T15:58:59Z-
dc.date.issued2006-05-
dc.identifier.citationRADPLAT: an alternative to surgery? 2006, 11 (5):469-80 Oncologisten
dc.identifier.issn1083-7159-
dc.identifier.pmid16720847-
dc.identifier.doi10.1634/theoncologist.11-5-469-
dc.identifier.urihttp://hdl.handle.net/10541/72314-
dc.description.abstractHead and neck cancer frequently presents at a late stage, leading to a poor prognosis despite optimal treatment with surgery and/or radiotherapy. Chemotherapy for advanced disease has shown little benefit as a single-modality treatment, and the use of concurrent chemoradiation is limited by problems with severe toxicity at higher doses. RADPLAT is the acronym used to describe a new technique, combining intra-arterial delivery of cisplatin with systemic neutralization by i.v. sodium thiosulphate, and concurrent radiotherapy. This allows very high cisplatin dose intensities to be used while potentially minimizing adverse systemic effects. Initial results suggest that excellent locoregional control rates are achievable in patients with unresectable disease, with a favorable side-effect profile when compared with conventional chemoradiation protocols. In addition, RADPLAT may potentially be of benefit in selected patients with resectable disease, allowing for preservation of organ function and quality of life without compromising locoregional control or survival. While current phase II data are encouraging, phase III randomized controlled trials are required in order to directly compare RADPLAT with i.v. chemoradiation therapy, the current standard of care. This article reviews the evolution of the RADPLAT concept, from initial clinical trials to its current application in the treatment of patients with advanced head and neck cancer.en
dc.language.isoenen
dc.subjectHead and Neck Canceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCarcinoma, Squamous Cell-
dc.subject.meshCisplatin-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshHead and Neck Neoplasms-
dc.subject.meshHumans-
dc.titleRADPLAT: an alternative to surgery?en
dc.typeArticleen
dc.contributor.departmentDepartment of Plastic Surgery, Christie Hospital, Southmoor Road, Manchester, United Kingdom, and Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands.en
dc.identifier.journalThe Oncologisten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.